Shionogi & Co. Ltd (SGIOF PINK) stock market data APIs
$18.9945
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
Shionogi & Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Shionogi & Co., Ltd. researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices. It offers and develops drugs in the areas of infectious diseases, COVID-19, tumors, sclerosis, pomp, fragile X syndrome, and other diseases. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Prev. Close
18.9945
Open
18.9945
High
18.9945
Low
18.9945
52 wk Range
11.611-19
Market Cap
16 167 M
P/E Ratio
14.0741
Shares Outstanding
851 M
Revenue
440 495 M
EPS
0.3201
Dividends (Yield)
0.0239
Beta
0.138
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Shionogi & Co. Ltd data using free add-ons & libraries
Get Shionogi & Co. Ltd Fundamental Data
Shionogi & Co. Ltd Fundamental data includes:
- Net Revenue: 440 495 M
- EBITDA: 184 653 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-28
- EPS/Forecast: 45.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shionogi & Co. Ltd News
New
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
BioVersys BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulati...
Can Shionogi’s Rally Continue After Key Drug Approval in 2025?
If you are on the fence about whether to buy, sell, or hold Shionogi stock, you are definitely not alone. Investors have been keeping a close eye on Shionogi’s price swings, wondering if there is mo...
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
Scientific Contributions at Congress Include Real-World Evidence on More Than 1,000 Cefiderocol Patients Findings from Antimicrobial Surveillance Program Will be Featured in Oral and Poster Presentat...
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
Application is based on results from SCORPIO-PEP, the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing COVID-19 following exposure to an infected individual...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
